CSPC Pharmaceutical Group’s Stock Price Dips to 6.67 HKD, Witnessing a 4.58% Decline

CSPC Pharmaceutical Group (1093)

6.67 HKD -0.32 (-4.58%) Volume: 204.32M

CSPC Pharmaceutical Group’s stock price stands at 6.67 HKD, experiencing a significant drop of -4.58% this trading session, with a high trading volume of 204.32M. The stock has seen a year-to-date percentage change of -7.02%, indicating a challenging market performance.

Latest developments on CSPC Pharmaceutical Group

Today, CSPC Pharmaceutical Group saw a surge in stock price following the announcement of a new heart medication deal with AstraZeneca. This collaboration marks a significant milestone for the company, as they continue to expand their portfolio in the pharmaceutical industry. Additionally, CSPC Pharmaceutical Group‘s stock price was also influenced by Astellas’ gene therapy pact and the unveiling of a new cell therapy site. These developments have generated excitement among investors, driving up the company’s stock value.

A look at CSPC Pharmaceutical Group Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, CSPC Pharmaceutical Group shows a promising long-term outlook. With a high score in Dividend and strong scores in Growth, Resilience, and Momentum, the company is well-positioned for future success. While the Value score is not as high as the others, the overall positive scores indicate that CSPC Pharmaceutical Group is a solid investment option.

CSPC Pharmaceutical Group Limited, a company that manufactures and sells pharmaceutical products, including vitamin C, antibiotics, and generic drugs, is also involved in developing innovative drugs and antibiotics. With its impressive Smart Scores across various factors, CSPC Pharmaceutical Group appears to be a reliable player in the pharmaceutical industry, poised for continued growth and success in the long term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma